ceftazidime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	559	72558-82-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ceftazidime hydrate ceftazidime biotum cefazid ceftacidin ceftazidine tazicef tazidime ceftazidime sodium ceftazidime pentahydrate	Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Molecular weight: 547.58 Formula: C22H23N6O7S2 CLOGP: -3.47 LIPINSKI: 2 HAC: 13 HDO: 4 TPSA: 188.39 ALOGS: -5.11 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ceftazidime hydrate
ceftazidime
biotum
cefazid
ceftacidin
ceftazidine
tazicef
tazidime
ceftazidime sodium
ceftazidime pentahydrate

Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.

Molecular weight: 547.58
Formula: C22H23N6O7S2
CLOGP: -3.47
LIPINSKI: 2
HAC: 13
HDO: 4
TPSA: 188.39
ALOGS: -5.11
ROTB: 9

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P
6	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	5 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	85 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	156.82 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.31 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.79 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 19, 1985	FDA	COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	155.58	20.53	56	8235	8872	56274904
Toxic epidermal necrolysis	84.66	20.53	48	8243	21994	56261782
Drug resistance	82.33	20.53	46	8245	20496	56263280
Acute kidney injury	78.86	20.53	133	8158	240630	56043146
Pseudomonas infection	77.19	20.53	35	8256	10036	56273740
Infective pulmonary exacerbation of cystic fibrosis	71.02	20.53	31	8260	8126	56275650
Pathogen resistance	69.69	20.53	28	8263	5972	56277804
Multiple organ dysfunction syndrome	68.52	20.53	59	8232	52711	56231065
Endophthalmitis	63.44	20.53	22	8269	3121	56280655
Hyperbilirubinaemia	61.28	20.53	30	8261	10205	56273571
Febrile neutropenia	60.38	20.53	76	8215	105469	56178307
Neutropenia	55.20	20.53	90	8201	158077	56125699
Drug reaction with eosinophilia and systemic symptoms	54.47	20.53	41	8250	30263	56253513
Septic shock	53.89	20.53	55	8236	60780	56222996
Sepsis	52.12	20.53	82	8209	139758	56144018
Fatigue	51.72	20.53	26	8265	788526	55495250
Adenoviral hepatitis	48.02	20.53	11	8280	340	56283436
Cytomegalovirus infection	45.96	20.53	31	8260	19265	56264511
Systemic inflammatory response syndrome	45.75	20.53	20	8271	5258	56278518
Vanishing bile duct syndrome	45.45	20.53	12	8279	673	56283103
Staphylococcal sepsis	45.37	20.53	22	8269	7327	56276449
Patent ductus arteriosus	44.37	20.53	18	8273	3933	56279843
Pancytopenia	41.63	20.53	58	8233	88657	56195119
Cholestasis	40.95	20.53	33	8258	26880	56256896
Peritonitis	40.93	20.53	27	8264	16175	56267601
Pyrexia	38.48	20.53	142	8149	418631	55865145
Myelosuppression	36.76	20.53	26	8265	17429	56266347
Neurotoxicity	36.72	20.53	25	8266	15770	56268006
Endometrial disorder	36.39	20.53	10	8281	653	56283123
Pain	36.26	20.53	27	8264	663157	55620619
Disseminated intravascular coagulation	36.20	20.53	26	8265	17859	56265917
Enterococcus test positive	35.51	20.53	11	8280	1095	56282681
Intensive care unit acquired weakness	35.50	20.53	10	8281	716	56283060
Suspected transmission of an infectious agent via product	34.87	20.53	8	8283	249	56283527
Hepatic failure	34.71	20.53	33	8258	33453	56250323
Venous haemorrhage	33.85	20.53	8	8283	284	56283492
Pseudomonal bacteraemia	33.43	20.53	11	8280	1329	56282447
Rash maculo-papular	32.87	20.53	30	8261	28877	56254899
Febrile bone marrow aplasia	32.70	20.53	17	8274	6555	56277221
Fungaemia	32.09	20.53	12	8279	2112	56281664
Bronchopulmonary aspergillosis	31.72	20.53	18	8273	8246	56275530
Graft versus host disease in gastrointestinal tract	31.67	20.53	13	8278	2926	56280850
Hypopyon	31.22	20.53	9	8282	700	56283076
Fungal sepsis	30.61	20.53	10	8281	1181	56282595
Abdominal discomfort	30.09	20.53	3	8288	277271	56006505
Bacteraemia	29.98	20.53	22	8269	15609	56268167
Peripheral sensorimotor neuropathy	29.64	20.53	10	8281	1305	56282471
Pulmonary haemorrhage	29.39	20.53	16	8275	6767	56277009
Graft versus host disease in liver	29.29	20.53	8	8283	511	56283265
Arthralgia	29.27	20.53	19	8272	501650	55782126
Respiratory failure	29.01	20.53	51	8240	95011	56188765
Acute generalised exanthematous pustulosis	28.76	20.53	18	8273	9851	56273925
Mucosal inflammation	27.97	20.53	33	8258	42777	56240999
Aspergillus infection	27.96	20.53	16	8275	7449	56276327
Micturition disorder	27.90	20.53	11	8280	2232	56281544
Aplasia	27.83	20.53	13	8278	3983	56279793
Encephalopathy	27.80	20.53	30	8261	35295	56248481
Eosinophilic pneumonia acute	27.76	20.53	7	8284	327	56283449
Blood bilirubin increased	27.44	20.53	29	8262	33325	56250451
Hepatocellular injury	27.23	20.53	26	8265	26488	56257288
Moraxella infection	26.92	20.53	7	8284	370	56283406
Linear IgA disease	25.90	20.53	9	8282	1284	56282492
Thrombocytopenia	25.89	20.53	60	8231	136164	56147612
Alopecia	25.46	20.53	6	8285	293452	55990324
Ascites	24.62	20.53	29	8262	37515	56246261
Tubulointerstitial nephritis	24.43	20.53	20	8271	16645	56267131
Haemophagocytic lymphohistiocytosis	24.29	20.53	16	8275	9556	56274220
Hepatomegaly	24.22	20.53	17	8274	11258	56272518
Hepatosplenic candidiasis	24.21	20.53	6	8285	261	56283515
Sweat test abnormal	24.13	20.53	4	8287	20	56283756
Graft versus host disease	23.97	20.53	14	8277	6767	56277009
Product contamination	23.88	20.53	7	8284	577	56283199
Foetal exposure during pregnancy	23.64	20.53	27	8264	33796	56249980
Renal failure	23.60	20.53	51	8240	110449	56173327
Congestive hepatopathy	23.10	20.53	10	8281	2566	56281210
Stenotrophomonas infection	23.09	20.53	9	8282	1772	56282004
Myelopathy	22.84	20.53	10	8281	2638	56281138
Cardiomyopathy	22.77	20.53	19	8272	16239	56267537
Respiratory gas exchange disorder	22.66	20.53	6	8285	340	56283436
Graft versus host disease in skin	22.63	20.53	10	8281	2697	56281079
Renal tubular necrosis	22.50	20.53	16	8275	10812	56272964
Fibrosis	22.08	20.53	11	8280	3880	56279896
Peripheral swelling	22.00	20.53	4	8287	234722	56049054
Premature baby	21.97	20.53	20	8271	19185	56264591
Distal intestinal obstruction syndrome	21.92	20.53	6	8285	386	56283390
Lower respiratory tract infection bacterial	21.85	20.53	6	8285	391	56283385
Status epilepticus	21.84	20.53	18	8273	15123	56268653
Fall	21.57	20.53	13	8278	357497	55926279
Hepatic necrosis	21.55	20.53	12	8279	5304	56278472
Clonus	21.17	20.53	11	8280	4238	56279538
Stevens-Johnson syndrome	20.98	20.53	21	8270	22642	56261134
Cardiac arrest	20.96	20.53	42	8249	86272	56197504
Acinetobacter infection	20.89	20.53	8	8283	1502	56282274
Cardiac tamponade	20.74	20.53	11	8280	4415	56279361

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endophthalmitis	312.09	19.52	93	10551	3523	31683177
Choroiditis	219.12	19.52	55	10589	1077	31685623
Pathogen resistance	187.99	19.52	80	10564	8621	31678079
Septic shock	138.74	19.52	139	10505	66019	31620681
Aplastic anaemia	136.27	19.52	65	10579	9138	31677562
Eye pain	132.42	19.52	70	10574	12234	31674466
Intraocular pressure increased	129.88	19.52	53	10591	5134	31681566
Uveitis	112.81	19.52	52	10592	6764	31679936
Drug resistance	95.40	19.52	72	10572	23381	31663319
Multiple organ dysfunction syndrome	93.88	19.52	115	10529	68088	31618612
Visual acuity reduced	92.59	19.52	60	10584	15283	31671417
Hyperbilirubinaemia	91.15	19.52	60	10584	15690	31671010
Toxic epidermal necrolysis	84.00	19.52	62	10582	19462	31667238
Pseudomonas infection	72.28	19.52	46	10598	11355	31675345
Drug reaction with eosinophilia and systemic symptoms	60.84	19.52	62	10582	29956	31656744
Febrile neutropenia	59.26	19.52	128	10516	121721	31564979
Drug ineffective	57.43	19.52	273	10371	395300	31291400
Eosinophilia	54.50	19.52	52	10592	23201	31663499
Fungal peritonitis	54.37	19.52	17	10627	756	31685944
Respiratory failure	52.10	19.52	109	10535	101340	31585360
Condition aggravated	47.93	19.52	142	10502	163867	31522833
Fatigue	45.95	19.52	28	10616	335178	31351522
Klebsiella infection	43.37	19.52	29	10615	7774	31678926
Pyrexia	42.00	19.52	207	10437	303633	31383067
Fungal sepsis	41.20	19.52	14	10630	811	31685889
Toxic skin eruption	40.80	19.52	31	10613	10149	31676551
Aspergillus infection	39.50	19.52	32	10612	11496	31675204
Fall	38.19	19.52	8	10636	186081	31500619
Bronchopulmonary aspergillosis	34.84	19.52	32	10612	13602	31673098
Acute kidney injury	34.72	19.52	185	10459	279529	31407171
Vascular pseudoaneurysm thrombosis	34.58	19.52	7	10637	48	31686652
Candida infection	33.68	19.52	34	10610	16224	31670476
Mucosal inflammation	33.39	19.52	49	10595	34378	31652322
Death	32.82	19.52	44	10600	360525	31326175
Clostridium difficile colitis	30.23	19.52	30	10614	14026	31672674
Acute generalised exanthematous pustulosis	30.13	19.52	21	10623	6019	31680681
Suspected transmission of an infectious agent via product	30.11	19.52	11	10633	789	31685911
Fungaemia	29.86	19.52	15	10629	2354	31684346
Respiratory distress	28.64	19.52	45	10599	33508	31653192
Product contamination	28.32	19.52	10	10634	650	31686050
Dizziness	28.11	19.52	16	10628	199131	31487569
Shock	27.62	19.52	36	10608	22609	31664091
Febrile bone marrow aplasia	27.34	19.52	22	10622	7824	31678876
Cardiac valve vegetation	27.29	19.52	9	10635	475	31686225
Pneumonia pseudomonal	26.84	19.52	16	10628	3513	31683187
Infective pulmonary exacerbation of cystic fibrosis	26.55	19.52	20	10624	6464	31680236
Candida pneumonia	26.45	19.52	8	10636	318	31686382
Cytokine release syndrome	26.03	19.52	30	10614	16612	31670088
Clostridium difficile infection	25.12	19.52	30	10614	17249	31669451
Bone marrow failure	24.50	19.52	38	10606	27970	31658730
Folliculitis	24.46	19.52	16	10628	4132	31682568
Aplasia	24.27	19.52	16	10628	4187	31682513
Acute respiratory distress syndrome	23.89	19.52	35	10609	24505	31662195
Sepsis	23.42	19.52	107	10537	151822	31534878
Stomatitis	23.33	19.52	45	10599	39393	31647307
Herpes zoster reactivation	23.29	19.52	7	10637	272	31686428
Arterial angioplasty	23.03	19.52	5	10639	50	31686650
Drug ineffective for unapproved indication	22.82	19.52	29	10615	17761	31668939
Pseudomembranous colitis	22.55	19.52	13	10631	2682	31684018
Chondritis	22.54	19.52	6	10638	149	31686551
Graft versus host disease	21.92	19.52	22	10622	10425	31676275
Listeriosis	21.47	19.52	9	10635	931	31685769
Flavobacterium infection	20.80	19.52	5	10639	81	31686619
Leukopenia	20.70	19.52	54	10590	57774	31628926
Cystic fibrosis	20.61	19.52	11	10633	1955	31684745
Depression	20.57	19.52	3	10641	90812	31595888
Cholestasis	20.52	19.52	33	10611	25042	31661658
Trichosporon infection	20.49	19.52	8	10636	689	31686011
Embolia cutis medicamentosa	20.07	19.52	6	10638	229	31686471
Hepatocellular injury	19.93	19.52	30	10614	21514	31665186
Device related sepsis	19.73	19.52	12	10632	2732	31683968
Gastroenteritis staphylococcal	19.65	19.52	6	10638	246	31686454

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endophthalmitis	369.17	16.77	112	17483	6143	70904706
Aplastic anaemia	291.73	16.77	121	17474	16595	70894254
Pathogen resistance	238.05	16.77	98	17497	13181	70897668
Choroiditis	217.77	16.77	53	17542	1248	70909601
Septic shock	180.69	16.77	178	17417	112080	70798769
Drug resistance	162.15	16.77	107	17488	38083	70872766
Toxic epidermal necrolysis	156.33	16.77	106	17489	39451	70871398
Multiple organ dysfunction syndrome	140.23	16.77	153	17442	108362	70802487
Pseudomonas infection	131.89	16.77	73	17522	18921	70891928
Drug reaction with eosinophilia and systemic symptoms	114.33	16.77	103	17492	57910	70852939
Intraocular pressure increased	111.40	16.77	51	17544	8850	70901999
Hyperbilirubinaemia	107.51	16.77	68	17527	22500	70888349
Eye pain	101.65	16.77	77	17518	34025	70876824
Acute kidney injury	100.24	16.77	301	17294	474323	70436526
Fatigue	100.00	16.77	40	17555	824279	70086570
Febrile neutropenia	96.75	16.77	178	17417	204140	70706709
Visual acuity reduced	89.79	16.77	66	17529	27864	70882985
Uveitis	86.79	16.77	51	17544	14794	70896055
Infective pulmonary exacerbation of cystic fibrosis	85.14	16.77	47	17548	12111	70898738
Respiratory failure	71.16	16.77	140	17455	168595	70742254
Eosinophilia	70.52	16.77	67	17528	40252	70870597
Pyrexia	70.37	16.77	317	17278	606635	70304214
Sepsis	65.15	16.77	169	17426	244376	70666473
Fungal peritonitis	62.39	16.77	19	17576	1053	70909796
Suspected transmission of an infectious agent via product	61.75	16.77	19	17576	1090	70909759
Bronchopulmonary aspergillosis	61.64	16.77	47	17548	20955	70889894
Aspergillus infection	61.47	16.77	44	17551	17824	70893025
Klebsiella infection	60.51	16.77	40	17555	14252	70896597
Fall	59.80	16.77	18	17577	444078	70466771
Fungaemia	59.42	16.77	26	17569	4056	70906793
Pain	57.95	16.77	43	17552	628773	70282076
Drug ineffective	57.83	16.77	414	17181	939338	69971511
Neutropenia	56.85	16.77	166	17429	256990	70653859
Acute generalised exanthematous pustulosis	55.47	16.77	39	17556	15358	70895491
Toxic skin eruption	54.56	16.77	43	17552	20119	70890730
Cholestasis	54.08	16.77	63	17532	47809	70863040
Aplasia	53.45	16.77	29	17566	7222	70903627
Product contamination	53.18	16.77	17	17578	1106	70909743
Mucosal inflammation	52.51	16.77	74	17521	67776	70843073
Fungal sepsis	49.97	16.77	18	17577	1685	70909164
Dizziness	43.66	16.77	31	17564	464110	70446739
Candida infection	43.40	16.77	48	17547	34425	70876424
Disseminated intravascular coagulation	42.68	16.77	47	17548	33551	70877298
Febrile bone marrow aplasia	42.33	16.77	30	17565	11961	70898888
Status epilepticus	41.45	16.77	40	17555	24486	70886363
Clostridium difficile colitis	41.12	16.77	43	17552	28953	70881896
Pancytopenia	40.77	16.77	105	17490	151002	70759847
Graft versus host disease	40.56	16.77	32	17563	14991	70895858
Rash maculo-papular	40.40	16.77	56	17539	50489	70860360
Peripheral swelling	39.08	16.77	6	17589	236557	70674292
Arthralgia	38.41	16.77	41	17554	503349	70407500
Poor quality product administered	38.30	16.77	18	17577	3313	70907536
Pain in extremity	37.88	16.77	17	17578	328065	70582784
Cytomegalovirus infection	37.86	16.77	48	17547	39710	70871139
Hypopyon	37.56	16.77	13	17582	1082	70909767
Hepatocellular injury	36.74	16.77	51	17544	46040	70864809
Drug intolerance	36.66	16.77	6	17589	225681	70685168
Vascular pseudoaneurysm thrombosis	35.97	16.77	7	17588	54	70910795
Drug ineffective for unapproved indication	35.87	16.77	46	17549	38492	70872357
Haemophagocytic lymphohistiocytosis	35.06	16.77	33	17562	19579	70891270
Intensive care unit acquired weakness	34.91	16.77	14	17581	1757	70909092
Thrombocytopenia	34.68	16.77	134	17461	238976	70671873
Rheumatoid arthritis	33.87	16.77	15	17580	291790	70619059
Venoocclusive liver disease	33.78	16.77	25	17570	10653	70900196
Endometrial disorder	33.64	16.77	10	17585	510	70910339
Pneumonia pseudomonal	33.25	16.77	19	17576	5227	70905622
Pseudomonal bacteraemia	33.01	16.77	15	17580	2557	70908292
Leukopenia	32.91	16.77	78	17517	106482	70804367
Adenoviral hepatitis	32.78	16.77	11	17584	834	70910015
Cardiac valve vegetation	32.45	16.77	11	17584	860	70909989
Renal tubular necrosis	32.21	16.77	34	17561	23137	70887712
Abdominal discomfort	32.11	16.77	7	17588	214651	70696198
Stevens-Johnson syndrome	32.07	16.77	42	17553	35865	70874984
Encephalopathy	32.02	16.77	56	17539	61605	70849244
Cystic fibrosis	31.21	16.77	17	17578	4264	70906585
Staphylococcal infection	31.04	16.77	51	17544	53353	70857496
Staphylococcal sepsis	30.77	16.77	26	17569	13401	70897448
Product preparation error	30.41	16.77	17	17578	4485	70906364
Respiratory distress	30.17	16.77	51	17544	54599	70856250
Anxiety	29.48	16.77	9	17586	220321	70690528
Joint swelling	29.41	16.77	13	17582	253198	70657651
Systemic inflammatory response syndrome	29.31	16.77	23	17572	10689	70900160
Device related sepsis	29.13	16.77	18	17577	5710	70905139
Headache	29.10	16.77	63	17532	580342	70330507
Bacteraemia	28.88	16.77	36	17559	29273	70881576
Alopecia	28.63	16.77	7	17588	198483	70712366
Venous haemorrhage	28.41	16.77	8	17587	336	70910513
Shock	28.21	16.77	42	17553	40383	70870466
Enterococcus test positive	28.05	16.77	12	17583	1771	70909078
Vanishing bile duct syndrome	27.68	16.77	11	17584	1348	70909501
Muscle spasms	27.62	16.77	3	17592	154043	70756806
Neurotoxicity	26.81	16.77	35	17560	29791	70881058
Myelosuppression	26.52	16.77	35	17560	30110	70880739
Noninfectious peritonitis	26.12	16.77	7	17588	244	70910605
Mucormycosis	25.89	16.77	19	17576	7995	70902854
Pseudomembranous colitis	25.84	16.77	16	17579	5095	70905754
Therapeutic product effect decreased	25.10	16.77	3	17592	143015	70767834
Retinal vasculitis	25.03	16.77	10	17585	1242	70909607
Hepatosplenic candidiasis	24.90	16.77	8	17587	529	70910320
Acute respiratory distress syndrome	24.79	16.77	40	17555	41214	70869635
Pseudomonal sepsis	24.66	16.77	16	17579	5521	70905328
Arterial angioplasty	24.53	16.77	5	17590	50	70910799
Peritonitis	23.99	16.77	31	17564	26128	70884721
Malaise	23.36	16.77	45	17550	432887	70477962
Peripheral sensorimotor neuropathy	23.21	16.77	12	17583	2710	70908139
Contraindicated product administered	23.19	16.77	3	17592	134609	70776240
Blood bilirubin increased	23.17	16.77	48	17547	59853	70850996
Swelling	22.98	16.77	9	17586	188530	70722319
Sinusitis	22.47	16.77	7	17588	169188	70741661
Micturition disorder	22.46	16.77	13	17582	3662	70907187
Hepatic necrosis	22.44	16.77	18	17577	8628	70902221
Nasopharyngitis	21.98	16.77	14	17581	222192	70688657
Renal failure	21.94	16.77	99	17496	188971	70721878
Generalised oedema	21.93	16.77	27	17568	21681	70889168
Flavobacterium infection	21.41	16.77	5	17590	98	70910751
Graft versus host disease in gastrointestinal tract	21.28	16.77	15	17580	5929	70904920
Myocardial infarction	21.24	16.77	8	17587	171637	70739212
Moraxella infection	20.96	16.77	7	17588	523	70910326
Stenotrophomonas infection	20.88	16.77	12	17583	3337	70907512
Cerebrovascular accident	20.80	16.77	5	17590	143465	70767384
Product use in unapproved indication	20.70	16.77	104	17491	207374	70703475
Gastroenteritis staphylococcal	20.57	16.77	6	17589	286	70910563
Trichosporon infection	20.35	16.77	8	17587	953	70909896
Burkholderia cepacia complex infection	20.22	16.77	6	17589	304	70910545
Bacterial sepsis	20.02	16.77	16	17579	7631	70903218
Transfusion	19.96	16.77	24	17571	18812	70892037
Insomnia	19.85	16.77	15	17580	217791	70693058
Musculoskeletal stiffness	19.82	16.77	6	17589	147754	70763095
Synovitis	19.76	16.77	4	17591	129224	70781625
Liver abscess	19.74	16.77	14	17581	5585	70905264
Sweat test abnormal	19.72	16.77	4	17591	39	70910810
Linear IgA disease	19.64	16.77	11	17584	2913	70907936
Contusion	19.50	16.77	4	17591	128032	70782817
Condition aggravated	19.33	16.77	176	17419	427459	70483390
Chondritis	19.32	16.77	5	17590	152	70910697
Ascites	19.30	16.77	48	17547	67499	70843350
Keratitis bacterial	19.25	16.77	5	17590	154	70910695
Pseudomonas test positive	18.89	16.77	9	17586	1707	70909142
Feeling abnormal	18.70	16.77	6	17589	142313	70768536
Hepatic failure	18.67	16.77	43	17552	57582	70853267
Bone marrow failure	18.64	16.77	39	17556	48971	70861878
Hepatic function abnormal	18.06	16.77	47	17548	67949	70842900
Acinetobacter infection	18.04	16.77	10	17585	2594	70908255
Myoclonus	17.84	16.77	27	17568	26328	70884521
Paraesthesia	17.64	16.77	7	17588	145530	70765319
Off label use	17.60	16.77	270	17325	742790	70168059
Back pain	17.57	16.77	25	17570	271127	70639722
Listeriosis	17.45	16.77	9	17586	2023	70908826
Graft versus host disease in skin	17.40	16.77	13	17582	5617	70905232
Eosinophilic pneumonia acute	17.16	16.77	7	17588	918	70909931
Syncope	17.00	16.77	10	17585	165699	70745150
Pancreatic failure	16.80	16.77	8	17587	1516	70909333

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DD02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD52	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50696	PBP3 inhibitor
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gonococcal meningitis	indication	151004
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Ecthyma gangrenosum	indication	17732003
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Pneumonia due to Streptococcus	indication	34020007
Pneumonia due to Pseudomonas	indication	41381004
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Rhinoscleroma	indication	72409005	DOID:11336
Endometritis	indication	78623009	DOID:1002
Septicemia due to Serratia	indication	82091000
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Infectious disease of abdomen	indication	128070006
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Meningococcal meningitis	indication	192644005
Proteus pneumonia	indication	195888009
Neonatal meningitis	indication	276674008
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Infection due to Staphylococcus aureus	indication	406602003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Sepsis due to Staphylococcus aureus	indication	448417001
Sepsis due to Pseudomonas	indication	448813005
Urinary tract infection caused by Klebsiella	indication	369001000119100
Enterobacter Osteomyelitis	indication
H. Influenzae Meningitis	indication
Pseudomonas Aeruginosa Osteomyelitis	indication
E. Coli Pelvic Inflammatory Disease	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Complicated Proteus UTI	indication
E. Coli Gynecological Infections	indication
Skin and Skin Structure Proteus Infection	indication
E. Coli Endometritis	indication
Haemophilus Septicemia	indication
Klebsiella Pneumoniae Peritonitis	indication
Inflammatory Disease of Female Pelvic Organs	indication
Skin and Skin Structure Serratia Infection	indication
E. Coli Cervicitis	indication
Enterobacter Pneumonia	indication
E. Coli Pelvic Cellulitis	indication
EnterobacterJoint Infection	indication
Staphylococcus Aureus Joint Infection	indication
Staphylococcus Peritonitis	indication
Klebsiella Pneumoniae Osteomyelitis	indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Klebsiella Joint Infection	indication
E. Coli Peritonitis	indication
Complicated UTI with Pseudomonas Aeruginosa	indication
Citrobacter Pneumonia	indication
Pseudomonas Aeruginosa Joint Infection	indication
Pyrexia of unknown origin	off-label use	7520000
Pseudotuberculosis	off-label use	36753006
Infection by Yersinia enterocolitica	off-label use	80960004
Melioidosis	off-label use	428111003	DOID:5052
Ventilator-acquired pneumonia	off-label use	429271009
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Diabetic Foot Infection	off-label use
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.53	acidic
pKa2	3.47	acidic
pKa3	13.61	acidic
pKa4	3.1	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	7112592	Jan. 7, 2026	A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	7112592	Jan. 7, 2026	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	7112592	Jan. 7, 2026	METHOD OF TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	Feb. 25, 2020	NEW CHEMICAL ENTITY
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	Feb. 25, 2025	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peptidoglycan synthase FtsI	Enzyme	FTSI_ECOLI	INHIBITOR	IC50	6.26	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	IC50	6.53	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	IC50	4.96	WOMBAT-PK	CHEMBL

External reference:

ID	Source
4017550	VUID
N0000145931	NUI
D00921	KEGG_DRUG
78439-06-2	SECONDARY_CAS_RN
73547-61-2	SECONDARY_CAS_RN
203418	RXNORM
4017550	VANDF
C0007559	UMLSCUI
CHEBI:3508	CHEBI
CHEMBL44354	ChEMBL_ID
CHEMBL1200768	ChEMBL_ID
D002442	MESH_DESCRIPTOR_UI
DB00438	DRUGBANK_ID
10762	IUPHAR_LIGAND_ID
9M416Z9QNR	UNII
5481173	PUBCHEM_CID
1047	MMSL
173313	MMSL
2299	MMSL
2303	MMSL
30973	MMSL
4383	MMSL
4384	MMSL
d00009	MMSL
002735	NDDF
006723	NDDF
006724	NDDF
36893000	SNOMEDCT_US
387200005	SNOMEDCT_US
725671004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ceftazidime and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3143	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	29 sections
Ceftazidime and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3145	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	29 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5082	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5082	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5084	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5084	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5086	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5086	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5092	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5093	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	25 sections
AVYCAZ	HUMAN PRESCRIPTION DRUG LABEL	2	0456-2700	POWDER, FOR SOLUTION	2 g	INTRAVENOUS	NDA	29 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-127	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-127	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-128	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-128	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-129	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-129	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-235	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-236	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-237	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	25 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-105	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRAMUSCULAR	NDA	24 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-106	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRAMUSCULAR	NDA	24 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-107	INJECTION, POWDER, FOR SOLUTION	170 mg	INTRAMUSCULAR	NDA	24 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-109	INJECTION, POWDER, FOR SOLUTION	200 mg	INTRAMUSCULAR	NDA	25 sections